Pennsylvania is currently home to 3293 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
NCT04080804
Recruiting
The aim of this study is to potentiate adaptive immunity to enhance the anti-tumor activity of anti-PD1 antibody by the addition of anti-CTLA4 antibody or anti-LAG3 antibody (relatlimab) given in subjects with resectable locally advanced HNSCC prior to surgical resection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Register for Updates
Pilot Testing PICTURE-THIS
NCT06086301
Recruiting
This is a single-center pilot study examining the feasibility and acceptability of a transitional rehabilitation intervention, PICTURE-THIS, among critical illness survivors and their families. The intervention activities include transitional care coordination and activity-based rehabilitation delivered by a specialist team and integrated into usual care. There are three components to the assessment of feasibility and acceptability in this study: 1. User testing the PICTURE-THIS protocol to wor... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
12/10/2024
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Post-intensive Care Syndrome, Transitional Care, Critical Care, Health Services
Register for Updates
Testing the Effect of ENDS Flavors on Neurotransmission
NCT05836051
Recruiting
The overarching goal of this translational proposal is to determine if neuroactive flavor chemicals can enhance the addiction potential of electronic nicotine delivery systems (ENDS) by altering brain function and behavior.
Gender:
ALL
Ages:
Between 21 years and 60 years
Trial Updated:
12/10/2024
Locations: Penn State Health, Hershey, Pennsylvania
Conditions: Tobacco Dependence
Register for Updates
Adaptive Trial Scheduling in Naming Treatment for Aphasia
NCT05653466
Recruiting
Aphasia is a language disorder caused by stroke and other acquired brain injuries that affects over two million people in the United States and which interferes with life participation and quality of life. Anomia (i.e., word- finding difficulty) is a primary frustration for people with aphasia. Picture-based naming treatments for anomia are widely used in aphasia rehabilitation, but current treatment approaches do not address the long-term retention of naming abilities and do not focus on using... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: Language Rehab and Cognition Lab, Department of Communication Sciences and Disorders, School of Health and Rehabilitation Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Aphasia, Stroke
Register for Updates
Balancing Effortful and Errorless Learning in Naming Treatment for Aphasia
NCT05653440
Recruiting
Aphasia is a language disorder caused by stroke and other acquired brain injuries that affects over two million people in the United States and which interferes with life participation and quality of life. Anomia (i.e., word- finding difficulty) is a primary frustration for people with aphasia. Picture-based naming treatments for anomia are widely used in aphasia rehabilitation, but current treatment approaches do not address the long-term retention of naming abilities and do not focus on using... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: Language Rehab and Cognition Lab, Department of Communication Sciences and Disorders, School of Health and Rehabilitation Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Aphasia, Stroke
Register for Updates
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
NCT04743791
Recruiting
Single center, randomized, placebo- controlled study to assess change in mucociliary clearance of moderate to severe asthma patients after treatment with dupilumab or placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: The University of Pittsburgh Asthma Institute at UPMC, Pittsburgh, Pennsylvania
Conditions: Asthma
Register for Updates
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and with Pembrolizumab
NCT04130516
Recruiting
This Phase 1/2, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and in combination with pembrolizumab. The study will include a dose escalation phase, a dose expansion phase, and phase 2A cohorts. Up to 200 patients will be accrued for this study. Up to 15 study sites in the United States will participate in the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Solid Tumor, Adult
Register for Updates
eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer
NCT05427240
Recruiting
This randomized non-inferiority study will use a 2x2 design where traditional standard-of-care pre-test (visit 1) and post-test (visit 2: disclosure) counseling delivered by a genetic counselor are replaced with a self-directed web-based eHealth intervention to provide critical data to inform optimal ways to deliver clinical genetic testing in eligible individuals, while maintaining quality of care and favorable cognitive, affective and behavioral outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Cancer
Register for Updates
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT03715933
Recruiting
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
12/09/2024
Locations: Children's Hospital of Philadelphia- Center for Childhood Cancer Research, Philadelphia, Pennsylvania
Conditions: Colorectal Adenocarcinoma, Ewing Sarcoma
Register for Updates
Intrapartum Glucose Control and Risk of Neonatal Hypoglycemia
NCT06643351
Recruiting
The purpose of this study is to assess whether a liberal intrapartum glycemic target range compared to usual care standard control ranges will lead to a decrease in the rate of neonatal hypoglycemia among pregnant patients in labor with diabetes.
Gender:
FEMALE
Ages:
All
Trial Updated:
12/07/2024
Locations: Magee-Women's Hospital of UPMC, Pittsburgh, Pennsylvania
Conditions: Gestational Diabetes Mellitus in Pregnancy, Pregestational Diabetes Mellitus, Neonatal Hypoglycemia
Register for Updates
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
NCT05668962
Recruiting
This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer. This research study involves the study drug selpercatinib in combination with standard of care treatments, I-131 and thyrotropin alfa (rhTSH).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
12/07/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer, Follicular Thyroid Cancer, Unresectable Thyroid Gland Carcinoma, Papillary Thyroid Cancer
Register for Updates
Safety and Efficacy of Anti-CD47, ALX148 in Combination with Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
NCT05467670
Recruiting
Immunotherapy with immune checkpoint inhibitors, including pembrolizumab, have emerged as a promising option in several solid cancers with durable effect and low toxicity profile. However, the benefit is limited to smaller subset of solid tumors. This trial involves the enhancement of current immune checkpoint-based immunotherapy with ALX148, an agent that inhibits CD47 (a trans-membrane protein that is highly expressed on the surface of many solid tumors as compared to normal cells).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Ovarian Cancer
Register for Updates